Nothing Special   »   [go: up one dir, main page]

AU714166B2 - Chiral organoboranes - Google Patents

Chiral organoboranes Download PDF

Info

Publication number
AU714166B2
AU714166B2 AU32669/97A AU3266997A AU714166B2 AU 714166 B2 AU714166 B2 AU 714166B2 AU 32669/97 A AU32669/97 A AU 32669/97A AU 3266997 A AU3266997 A AU 3266997A AU 714166 B2 AU714166 B2 AU 714166B2
Authority
AU
Australia
Prior art keywords
compound
formula
general formula
compounds
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU32669/97A
Other versions
AU3266997A (en
Inventor
Marc Bonato
Jean-Bernard Cazaux
Michel Follet
Jean-Marc Kamenka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Expansia SA
Original Assignee
Expansia SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Expansia SA filed Critical Expansia SA
Publication of AU3266997A publication Critical patent/AU3266997A/en
Application granted granted Critical
Publication of AU714166B2 publication Critical patent/AU714166B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/027Organoboranes and organoborohydrides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Description

Chiral oranoboranes The invention relates to chiral organoboranes, the processes for their preparation and their use in particular as an asymmetrical reducing agent.
Thus, a subject of the invention is the compounds of general formulae I and II 1 B- X RB/R1 LiI m"R 2 X 2
H
I II in which either R 1 and R 2 represent, independently, a hydrogen atom or an alkyl or cycloalkyl radical, or R 1 and R 2 represent together a saturated divalent hydrocarbon group; Xi represents a halogen atom; and
X
2 represents a hydrogen or halogen atom.
In the definitions indicated above, the expression halogen represents a fluorine, chlorine, bromine or iodine atom, preferably fluorine, chlorine and bromine. The expression alkyl preferably represents a linear or branched alkyl radical having 1 to 6 carbon atoms, and in particular an alkyl radical having 1 to 4 carbon atoms such as the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl radicals.
The saturated cycloalkyl radicals can be chosen from the radicals having 3 to 7 carbon atoms such as the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl radicals, optionally substituted by a lower alkyl group.
The expression saturated divalent hydrocarbon group contains 6 to 8 carbon atoms and can be represented by a group of bicyclo type or and preferably the type A subject of the invention is also a preparation process for the compounds of general formula I as defined above, characterized in that a compound of general formula III B H 2 is reacted with an appropriate unsaturated hydrogenated hydrogen compound in order to obtain a compound of formula IV in which R 1 and R 2 are as defined above, which product of formula IV is reacted with an organolithium compound of formula R'Li in which R' represents an organic group, in order to obtain the compound of formula I.
The expression an appropriate unsaturated hydrogenated hydrogen compound represents a hydrocarbon compound containing one or two double bond(s).
The expression organic group represents an alkyl or aryl radical, and preferably an alkyl radical such as tert-butyl.
Thus, the reaction of a cycloalkyldiene containing 6 to 8 carbon atoms with the compound of formula III, allows a compound of formula I to be obtained in which Ri M
M
and R 2 represent together a saturated divalent hydrocarbon group of 6 to 8 atoms respectively. Similarly, the obtaining of an alkyl and/or cycloalkyl radical on the boron atom of the compound of formula I, is achieved by reacting the corresponding alkene and/or cycloalkene respectively, with the compound of formula III. This means that a compound of formula I in which Ri represents an alkyl radical and R 2 a cycloalkyl radical is obtained by reacting the compound of formula III with an alkene having the same number of carbon atoms as the desired cycloalkyl radical. Of course, Ri and R 2 can represent the same radical.
A subject of the invention is also a preparation process for the compounds of general formula II as defined above. The preparation process for a compound of formula II in which Xi has the meaning indicated above and X 2 represents hydrogen, is characterized in that a compound of general formula III as defined above, is reacted with one mole of a hydrogen halide of formula HX 1 in which XI has the meaning indicated above. The preparation process for a compound of formula II in which X 1 has the meaning indicated above and X 2 represents a halogen, is characterized in that a compound of general formula III as defined above is reacted with one mole of a hydrogen halide HXI and with one mole of a hydrogen halide HX 2 Of course, Xi and X 2 can represent the same halogen atom.
The starting compound III is known, it can be prepared by the hydroboration of 2myrtenl 1,3-dithiane by diborane or by a complex of diborane with a Lewis acid (Patent EP 61408).
The compounds of formula I and II can thus be prepared in optically active form, starting from compound III in optically active form.
The compositions of the present invention are useful as an asymmetrical reducing agent.
A subject of the invention is also the use of the compounds of formulae I and II for asymmetrical reductions. Preferably, the compounds of the present invention are used for the stereospecific reduction of ketone or imine function(s). The stereospecfic reduction of a ketone or of an imine, consists in reacting the ketone or the imine with an enantiomer of a compound of general formula I or II.
The following examples are presented in order to illustrate the invention and should in no event be considered to limit the scope of the invention.
Example 1 Preparation of compound in which Xi X2 Cl 3 g (11 mmol) of compound is suspended in 60 ml of anhydrous ethyl ether in a 100 ml flask under nitrogen atmosphere. The suspension is then cooled down in a refrigerating bath to -60 0 C and 5.6 ml (25 mmol) of 4.5N hydrochloric ether is rapidly introduced. The bath is removed, then the temperature is maintained at -10 0 C for 2 hours 30 minutes. The product precipitates in the form of a white powder. The solvent is eliminated under vacuum. The overall yield is 83.7%, calculated on the basis of 2myrtenyl-1,3-dithiane borane.
The white solid is recovered in 20 ml of anhydrous tetrahydrofuran and used as it is in the reductions.
Example 2.
Preparation of a compound of formula I, in which B--R 1 represents B R2 37 g of compound is poured into 140 ml of anhydrous tetrahydrofuran. The temperature is taken to 0°C and 20 ml of cyclooctadiene in 20 ml of tetrahydrofuran is added over 30 minutes. The reaction mixture is then heated under reflux overnight. After cooling down to -70 5 0 C, 81 ml of a 1.7M solution of t-butyllithium in pentane is added over 45 minutes. The reaction mixture is maintained at 70 5 0 C for another two hours, then the different solvents as well as the excess cyclooctadiene are eliminated Sunder reduced pressure and at ambient temperature. The residue obtained is taken up in 100 ml of MTBE. After agitation for 2 hours at ambient temperature, then decanting at 0 C, the liquid phase is separated. The white solid residue is washed with 100 ml of heptane at ambient temperature which is then immediately eliminated by filtering. After a last additional washing at ambient temperature with 100 ml of MTBE and drying under reduced pressure, 45.9 g of white crystals is obtained (yield These crystals are kept at 4°C under argon and sheltered from light.
Example 3.
Use of compound II obtained in Example 1 for the reduction shown below: o o O ,H e °T~i1
TTY)
CH
3 Cl CH3 N S 1 g (3.15 mmol) of compound I solubilized in 10 ml of anhydrous tetrahydrofuran is added, at 0°C under nitrogen atmosphere, to a solution of 3.7 g (11 mmol) of compound as obtained in Example 1, solubilized in 20 ml of anhydrous tetrahydrofuran. The solution is agitated for 48 hours at 25 0 C. The solvent is then eliminated under reduced pressure. The residue is taken up in 60 ml of ethyl ether and 2.6 g (25 mmol) of diethanolamine is added. The insoluble part is removed by filtering and the filtrate is Sconcentrated to dryness.
The residue represents 0.6 g of compound 2 with an enantiomeric composition of Example 4 Use of compound I obtained in Example 2, for the reduction of I 2 as defined above.
g of compound I as obtained above is dissolved in 45 ml of anhydrous tetrahydrofuran Sunder an inert atmosphere. The reaction mixture is then held at a temperature of approximately -78 0 C using thermostat control, and 0.5 equivalent of compound I diluted in 10 ml of tetrahydrofuran is added over 30 minutes. The reaction is continued for 2 hours at approximately -78 0 C. The excess borohydride is neutralized with alcohol. The reaction mixture is dried under vacuum. The residue obtained is redissolved in 25 ml of ethyl ether and the organic phase is washed with water to a neutral pH. After dehydration with sodium sulphate, filtering and drying under vacuum, 8.9 g of a mixture is recovered which is separated by chromotography on a silica column. The ratio of the enantiomers of compound 2 is 96% Example Use of compound of formula I, in which B-RI represents B R2 prepared in situ for the reduction of 1>2 as defined above.
a) Preparation of compound 214.2 g myrtenyl dithiane dissolved in THF (1280 ml) is added to 9-bora bicyclco nonane. After dissolution, the reaction mixture is heated under reflux overnight, in order to complete the reaction, then cooled down to -80 0 C. Then tert butyl lithium is added over less than one hour, while maintaining the temperature between -60 and 800C.
Then, compound 1 )100 g) is added by portions over less than 15 minutes. The mixture is maintained for two hours at -60 0 C. At this precise moment compound 1 is entirely converted.
After treating as in the previous example, compound 2 is crystallized from hexane (530 ml), in order to produce 52.1 g with a composition 98.2% b) Preparation of compound 2 39.5 g of compound III is dissolved in THF (240 ml). The solution is cooled down to 0 C and incorporated in a solution of 1,5 cyclo octadien (15.9 g) in THF (45 ml).
-L
7 The resulting solution is heated at reflux overnight, then treated as above with tBuLi in order to reduce compound 1 (21 g) and produces, after usual treatment, compound 2 g ee 100%).

Claims (10)

1. The compounds of general formula I and II BeRIB-X B, R I Li I 'R2 x 2 H I II in which either RI and R 2 represent, independently, a hydrogen atom or an alkyl or cycloalkyl radical, or R, and R 2 represent together a.saturated divalent hydrocarbon group; X, represents a halogen atom; and X 2 represents a hydrogen or halogen atom.
2. The compounds of general formula I as defined in claim 1, characterized in that R, and R 2 independently, a hydrogen atom or a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-buytl, tert-butyl radical, or a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 20 cycloheptyl or cyclooctyl radical, optionally substituted by a lower alkyl group.
3. The compounds of general formula I as defined in claim 1 in which R, and R 2 represent together a saturated divalent hydrocarbon group containing 8 carbon atoms, and preferably a group such as B-RI B represents
4. The compounds of general formula II as defined in claim 1, in which X, and X 2 represent a halogen atom and preferably a chlorine atom. ii i; i i ii i Process for the preparation of the products of general formula I as defined in one of claims 1 to 2, characterized in that a compound of general formula I11 BH 2 is reacted with an appropriate unsaturated hydrogenated compound, in order to obtain a compound of formula IV B-RI Rz IV in which R, and R 2 are as defined above, which product of formula IV is reacted with an organolithium compound of formula R'Li 20 in which R' represents an organic group, in order to obtain the compound of formula I. C
6. Process for the preparation of the products of general formula 11 as defined in claim 1, in which X, has the meaning indicated in claim 1 and X 2 represents hydrogen, characterized in that a compound of general formula III as defined in claim 5 is reacted 25 with one mole of a hydrogen halide of formula HX, in which X, has the meaning indicated above. Co C*
7. Process for the preparation of the products of general formula II as defined in claim 1, in which Xi has the meaning indicated in claim 1 and X 2 represents a halogen, characterized in that a compound of general formula III as defined in claim 5 is reacted with one mole of a hydrogen halide of formula HXI in which X, has the meaning indicated above and one mole of a hydrogen halide of formula HX 2 in which X 2 has the meaning indicated above.
8. Use of the products of formula I or II as defined in any one of claims I to 4, as an asymmetrical reducing agent and in particular for the asymmetrical reduction of ketones or imines.
9. Use according to claim 8, in which the ketone is the compound of formula 1 CH 3 0 a. .0. .0a 0 a a a. a a. a Compounds according to claim 1 and as herein described with reference to the examples.
11. The process according to claim 5 and as herein described with reference to the examples.
12. The process according to claim 6 and as herein described with reference to the examples. DATED this 28th day of October 1999 SOCIETE D'EXPANSION SCIENTIFIQUE EXPANSIA WATERMARK PATENT TRADEMARK ATTORNEYS 290 BURWOOD ROAD HAWTHORN VICTORIA 3122 AUSTRALIA VAX DOC029 AU3266997: IAS/CLR/RES
AU32669/97A 1996-06-13 1997-06-12 Chiral organoboranes Ceased AU714166B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9607331A FR2749847B1 (en) 1996-06-13 1996-06-13 CHIRAL ORGANOBORANES
FR96/07331 1996-06-13
PCT/FR1997/001050 WO1997047628A1 (en) 1996-06-13 1997-06-12 Chiral organoboranes

Publications (2)

Publication Number Publication Date
AU3266997A AU3266997A (en) 1998-01-07
AU714166B2 true AU714166B2 (en) 1999-12-23

Family

ID=9493012

Family Applications (1)

Application Number Title Priority Date Filing Date
AU32669/97A Ceased AU714166B2 (en) 1996-06-13 1997-06-12 Chiral organoboranes

Country Status (8)

Country Link
EP (1) EP0918779A1 (en)
JP (1) JP2000511922A (en)
AU (1) AU714166B2 (en)
CA (1) CA2257678A1 (en)
FR (1) FR2749847B1 (en)
NO (1) NO985832L (en)
NZ (1) NZ333451A (en)
WO (1) WO1997047628A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2236499A (en) * 1999-01-19 2000-08-07 Mine Safety Appliances Company Synthesis of alkali metal substituted borohydride reagents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA821644B (en) * 1981-03-25 1983-01-26 Expansia Sa Borane complexes

Also Published As

Publication number Publication date
NZ333451A (en) 1999-08-30
AU3266997A (en) 1998-01-07
CA2257678A1 (en) 1997-12-18
WO1997047628A1 (en) 1997-12-18
FR2749847A1 (en) 1997-12-19
JP2000511922A (en) 2000-09-12
NO985832D0 (en) 1998-12-11
NO985832L (en) 1998-12-14
FR2749847B1 (en) 1998-11-06
EP0918779A1 (en) 1999-06-02

Similar Documents

Publication Publication Date Title
Chong et al. Asymmetric synthesis of trans-2, 5-diphenylpyrrolidine: A C2-symmetric chiral amine
JP3723241B2 (en) Optically active phosphorus compound
Imamoto et al. Reactions of Phosphine-Monoiodoboranes with 4, 4'-Di-tert-butylbiphenylide and Electrophiles. Trial of Generation of Tricoordinate Boron Anions and Synthesis of B-Functionalized Phosphine-Boranes
NO302756B1 (en) Chiral phospholane transition metal catalysts
Oshiki et al. Stereospecific reduction of menthyloxyphosphine-boranes with one-electron reducing agents
Crowe et al. 2-Metallated Oxazoles; pKa Dependent Deuterations, NMR Studies and Palladium Catalysed Coupling.
Kitamura et al. Asymmetric synthesis of β-hydroxy sulfonic acids by BINAP/Ru-catalyzed hydrogenation
US5554776A (en) Racemic metallocene complexes and their preparation
AU714166B2 (en) Chiral organoboranes
Michel et al. Equilibria between nonclassical and classical boron compounds, competition between aromaticity in two and three dimensions
Lakshmikantham et al. Novel oxidative rearrangement of o-xylene-. alpha.,. alpha.'-diylidenebis (4, 5-dicarbomethoxy-1, 3-dithiole)
US5210196A (en) Chiral sultams
US6489526B2 (en) Method for synthesis of hydrocarbyl bridged indenes
US4173590A (en) Process for making tetramethyldiphosphinomethane
JP2917552B2 (en) Method for producing α-methylenecyclopentanone derivative
Pietrusiewicz et al. OPTICALLY ACTIVE PHOSPHINE OXIDES. 6.1 CONJUGATE ADDITION OF THIOLS AND ALCOHOLS TO (-)-(S)-METHYL-PHENYLVINYLPHOSPHINE OXIDE
US5159116A (en) Chemically and optically pure B-halodiiso-2-ethylapopinocampheylboranes
JP3740180B2 (en) Method for producing biscyclopentadienyl compound
JP4077103B2 (en) Method for producing tris (perfluoroalkylsulfonyl) methide salt
US5220072A (en) Process of synthesizing chemically and optically pure B-halodiiso-2-ethylapopinocampheylboranes
DE69526154T2 (en) Production of organohaloboranes and alkoxyorganoboranes
AU742623B2 (en) Method for preparing tetrakis (pentafluorophenyl) borate derivatives
JPS63135393A (en) Production of alkylsilyl cyanide
GB1579541A (en) Process for the production of (1,1 - dithien - (3)-yl - 1 - hydroxy - (3) - propyl) - (1-phenyl - 1 - hydroxy - (2) - propyl)-amine and (1,1 - dithien - (3) - yl-(1) - propen - (3) - yl) - (1 - phenyl-1 - hydroxy - (2) - propyl)- amine
KR890004125B1 (en) New phosphino pyrrolidine compound

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired